Armistice Capital, LLC and Steven Boyd filed a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 343,957 shares of Bone Biologics Corporation common stock as of September 30, 2026.
Key Highlights
- Reporting persons: Armistice Capital, LLC (Delaware) and Steven Boyd (United States) filed jointly as the "Reporting Persons."
- Shares beneficially owned: Each reporting person reported beneficial ownership of 343,957 shares of Bone Biologics common stock, $0.001 par value per share.
- Percent of class: The 343,957 shares represent 9.99% of the class, according to the filing.
- Voting and dispositive power: Both reporting persons reported 0 sole voting power and 0 sole dispositive power, with shared voting and shared dispositive power each at 343,957 shares.
- Direct holder: The filing identifies Armistice Capital Master Fund Ltd. as the direct holder of the shares, with Armistice Capital, LLC serving as its investment manager.
- Triggering event date: The date of the event requiring the filing was reported as September 30, 2026.
Armistice Capital and Boyd Disclose Near-10% Position in Bone Biologics
According to the Schedule 13G filed on November 16, 2026, Armistice Capital, LLC and Steven Boyd collectively reported beneficial ownership of 343,957 shares of Bone Biologics Corporation common stock. Bone Biologics, whose principal executive offices are listed at 2 Burlington Woods Drive, Ste 100, Burlington, MA 01803, has common stock with CUSIP number 098070600. The filing does not identify an exchange or ticker symbol in its text.
The filing states that Armistice Capital, LLC serves as the investment manager of Armistice Capital Master Fund Ltd., described as "the direct holder of the Shares," and that "pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund." Steven Boyd, identified as the managing member of Armistice Capital, LLC, "may be deemed to beneficially own the securities of the Issuer held by the Master Fund." The Master Fund is described as a Cayman Islands exempted company and an investment advisory client of Armistice Capital, and the filing states that it "has the right to receive dividends from, or the proceeds from the sale of, the reported securities."
The filing further states that "the Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital." The certification included in the filing states that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."
What Was Disclosed
Armistice Capital, LLC and Steven Boyd disclosed a combined beneficial ownership of 343,957 shares, equaling 9.99% of Bone Biologics Corporation common stock, with all voting and dispositive power held on a shared basis as of September 30, 2026.




Please wait processing your request...